when will semaglutide be generic Available? Demand Rising for 'Bootlegged' Weight-Loss

Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors

Makin recommends

10.1007/s10557-018-6773-2 84

Dulaglutide and Tirzepatide Litigation British Columbia Class Action On February 11, 2026, Siskinds filed a proposed class action in the Supreme Court of British Columbia, alleging that dulaglutide drugs (Trulicity) and tirzepatide drugs (Mounjaro, Zepbound) manufactured and marketed by the Eli Lilly group of pharmaceutical companies were defective, and that the manufacturers failed to adequately warn users, and their health care providers, that semaglutide drugs increase the risk of serious complications, including gallbladder disorders, severe gastrointestinal injuries (including gastroparesis, or stomach paralysis), blood clots, aspiration during surgery, necrotizing pancreatitis, malnutrition, and vision loss (non-arteritic anterior ischemic optic neuropathy)

This dual mechanismrapid weight loss combined with potential direct effects on gallbladder functionmay explain the observed association between GLP-1 therapy and gallstone risk